Smartleaf Asset Management’s Structure Therapeutics GPCR Stock Holding History

Smartleaf Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$747	Buy	+17	New	+$1.16K	﹤0.01%	3164

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Smartleaf Asset Management's GPCR Position: Q1 2026 in Review

Smartleaf Asset Management opened a new position in Structure Therapeutics (GPCR) in Q1 2026: 17 shares worth $747. The stake represents ﹤0.01% of the portfolio and ranks #3164 among its holdings.

196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Smartleaf Asset Management held 17 shares of Structure Therapeutics worth $747 as of Q1 2026.
Structure Therapeutics was a new Smartleaf Asset Management position in Q1 2026.
Structure Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #3164 holding.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.